PHYSIOLOGICAL BASED PHARMACOKINETIC (PBPK) MODELING OF PYROTINIB TO UNDERSTAND THE INTERPLAY BETWEEN CYP3A4 AND P-GP WHEN CO-ADMINISTRATED WITH CYP3A4 INHIBITORS/INDUCERS
| Title | PHYSIOLOGICAL BASED PHARMACOKINETIC (PBPK) MODELING OF PYROTINIB TO UNDERSTAND THE INTERPLAY BETWEEN CYP3A4 AND P-GP WHEN CO-ADMINISTRATED WITH CYP3A4 INHIBITORS/INDUCERS |
|---|---|
| Description | Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for treating HER2-positive advanced solid tumors. CYP3A4 primarily metabolizes Pyrotinib, and in vitro assay suggested a potential substrate for P-gp efflux transporter. The objective was to use the PBPK model of pyrotinib to understand how the interplay of CYP3A4 and P-gp can affect the drug-drug interactions (DDI) for pyrotinib when co-administered with CYP3A4 inhibitors/inducers. |
| Organism | Homo sapiens |
| Data Type | Other Type of Metabolome Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA011231 |
| Release Date | 2024-08-16 |
| Submitter | miao wang (miao.wang.mw5@hengrui.com) |
| Organization | Jiangsu Hengrui Pharmaceutical Co., Ltd |
| Submission Date | 2022-08-16 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX001615-01 | PHYSIOLOGICAL BASED PHARMACOKINETIC (PBPK) MODELING OF PYROTINIB TO UNDERSTAND THE INTERPLAY BETWEEN CYP3A4 AND P-GP WHEN CO-ADMINISTRATED WITH CYP3A4 INHIBITORS/INDUCERS | 1 | Other Type of Metabolome Data | 132.7 KB | xlsx | 0 | Controlled |